Kotsantis Panagiotis, Jones Rebecca M, Higgs Martin R, Petermann Eva
School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
Adv Clin Chem. 2015;69:91-138. doi: 10.1016/bs.acc.2014.12.003. Epub 2015 Feb 7.
Deregulated DNA replication occurs in cancer where it contributes to genomic instability. This process is a target of cytotoxic therapies. Chemotherapies exploit high DNA replication in cancer cells by modifying the DNA template or by inhibiting vital enzymatic activities that lead to slowing or stalling replication fork progression. Stalled replication forks can be converted into toxic DNA double-strand breaks resulting in cell death, i.e., replication stress. While likely crucial for many cancer treatments, replication stress is poorly understood due to its complexity. While we still know relatively little about the role of replication stress in cancer therapy, technical advances in recent years have shed new light on the effect that cancer therapeutics have on replication forks and the molecular mechanisms that lead from obstructed fork progression to cell death. This chapter will give an overview of our current understanding of replication stress in the context of cancer therapy.
在癌症中,DNA复制失调,这会导致基因组不稳定。这一过程是细胞毒性疗法的靶点。化疗通过修饰DNA模板或抑制导致复制叉进展减缓或停滞的重要酶活性,利用癌细胞中高活性的DNA复制。停滞的复制叉可转化为有毒的DNA双链断裂,导致细胞死亡,即复制应激。虽然复制应激可能对许多癌症治疗至关重要,但由于其复杂性,人们对它的了解甚少。尽管我们对复制应激在癌症治疗中的作用仍然知之甚少,但近年来的技术进步为癌症治疗药物对复制叉的影响以及从受阻的复制叉进展到细胞死亡的分子机制提供了新的线索。本章将概述我们目前对癌症治疗背景下复制应激的理解。